Molecule | Jotup

Noor Riyadh 2023: The world’s largest annual festival of light and art returns to Saudi Arabia’s Capital, with over 120 artworks by more than 100 local and international artists

Retrieved on:

Thursday, November 30, 2023

Molecule, Cosmos, Moon, Guinness, Tuwaiq, School, Random International, White people, Desert, KAFD, Kingdom Centre, Identity, TVC, Connectivity, Metal, Exhibition, Light, Argote, Social, Growth, Memory, Sans, Metaphor, House, Life, Interior design

RIYADH, Saudi Arabia, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Noor Riyadh, the world's largest light art festival, will return to Saudi Arabia's capital for its third edition from November 30 to December 16, 2023. More than 120 artworks, large-scale installations and immersive projections will light up the city, bringing art to the people and boosting the creative economy. The event supports the Riyadh Art objective of transforming Riyadh into an awe-inspiring 'gallery without walls', engaging diverse audiences, transcending boundaries, and integrating art into the urban fabric.

Key Points:

Photos © Noor Riyadh 2023, a Riyadh Art Program
RIYADH, Saudi Arabia, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Noor Riyadh, the world's largest light art festival, will return to Saudi Arabia's capital for its third edition from November 30 to December 16, 2023.
More than 120 artworks, large-scale installations and immersive projections will light up the city, bringing art to the people and boosting the creative economy.
The event supports the Riyadh Art objective of transforming Riyadh into an awe-inspiring 'gallery without walls', engaging diverse audiences, transcending boundaries, and integrating art into the urban fabric.
Among the highlights at Noor Riyadh is a number of site-specific commissions by 35 established and emerging Saudi artists.

Praxis Precision Medicines to Showcase Largest Pipeline of Precision Epilepsy Programs and Breadth of Commitment to Epilepsy Treatments at Upcoming Meetings

Retrieved on:

Tuesday, November 28, 2023

Presentations at the American Epilepsy Society (AES) Annual Meeting, as well as related scientific and patient advocacy meetings, will cover new patient data, updates on clinical progress and new paradigms for developing epilepsy therapies.

Key Points:

Presentations at the American Epilepsy Society (AES) Annual Meeting, as well as related scientific and patient advocacy meetings, will cover new patient data, updates on clinical progress and new paradigms for developing epilepsy therapies.
ET [Platform D | Epilepsy Therapies]
Summary: Combined preclinical and clinical data demonstrate PRAX-628 is differentiated from standard of care, with the potential to be best-in-class for focal epilepsy.
Summary: This study provides novel insights into the clinical validity of commonly used preclinical seizure models across the clinical epilepsy spectrum.
Oral presentation highlighting clinical updates from our PRAX-562 small molecule platform at the annual clinician, researcher, and family gathering for SCN8A

Cognition Therapeutics Presents Preclinical Data Identifying Pathways Impacted by Sigma-2 Receptor Modulators in Alzheimer’s and Parkinson’s Diseases

Retrieved on:

Wednesday, November 15, 2023

Molecule, Alzheimer's disease, Cell, Autophagy, Research, Parkinson's disease, Therapy, Disease, Metabolism, Cognition, Genomics, Sympathetic nervous system, Deficit spending, Lewy body, Society, Pharmaceutical industry, Residential care, Generic drug, Dementia

NEW YORK, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX) is presenting in vivo preclinical results at the Society for Neuroscience’s annual meeting illuminating the role of sigma-2 (σ-2) receptor modulators, including CT1812, in models of Alzheimer's and Parkinson’s diseases.

Key Points:

NEW YORK, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX) is presenting in vivo preclinical results at the Society for Neuroscience’s annual meeting illuminating the role of sigma-2 (σ-2) receptor modulators, including CT1812, in models of Alzheimer's and Parkinson’s diseases.
The effect of two chemically distinct σ-2 receptor modulators in a mouse model of Alzheimer’s disease on gene and protein expression are presented.
Fox Foundation grant award is presented defining the impact of σ-2 receptor modulators on gene and protein expression.
In two different rat models of Parkinson’s disease, the same two σ-2 receptor modulators are shown to effect pathways associated with Parkinson's disease, including cell survival, metabolism, autophagy, and protein/lipid transport.

Athira Pharma Presents Preclinical Data Highlighting Fosgonimeton’s Neuroprotective Effects Against Amyloid-β-Induced Pathological Alterations and Neuroinflammation in Models of Alzheimer’s Disease

Retrieved on:

Wednesday, November 15, 2023

Molecule, ISCB Senior Scientist Award, Annual general meeting, HGF, Cell proliferation, Athira Pharma, Neuron, Microglia, LPS, Oxidative stress, Neurogenesis, Neuroinflammation, Society, Pharmaceutical industry, Medical imaging, Neuroscience, Neurotrophic factors

“We continue to build the body of preclinical evidence supporting the continued development of fosgonimeton to treat AD and other debilitating neurodegenerative diseases,” said Kevin Church, Ph.D., Chief Scientific Officer, Athira Pharma.

Key Points:

“We continue to build the body of preclinical evidence supporting the continued development of fosgonimeton to treat AD and other debilitating neurodegenerative diseases,” said Kevin Church, Ph.D., Chief Scientific Officer, Athira Pharma.
“Our latest data demonstrate consistent neuroprotective effects of fosgonimeton and provide insights into the mechanisms by which it preserves neurons from degeneration and reduces neuroinflammation.
Wei Wu, Ph.D., Senior Scientist II, Athira Pharma, presented preclinical research demonstrating the cellular mechanisms by which fosgonimeton induces anti-inflammatory effects in BV2 microglia cells.
The anti-inflammatory effects of fosgonimeton demonstrated in these models suggest it may have the potential to help reduce neuroinflammation, a key pathological feature of several neurodegenerative diseases.

Annexon Reports Significant Progress with its Priority Programs and Third Quarter 2023 Financial Results

Retrieved on:

Monday, November 13, 2023

EMA orphan drug designation requires that a novel rare disease therapeutic demonstrates the potential for significant benefit over available therapies.

Key Points:

EMA orphan drug designation requires that a novel rare disease therapeutic demonstrates the potential for significant benefit over available therapies.
Importantly, Annexon also announced that it has achieved target enrollment of 225 patients in the randomized, double-blind, placebo-controlled Phase 3 trial of ANX005 in patients with GBS.
Research and development (R&D) expenses: R&D expenses were $27.9 million for the quarter ended September 30, 2023, reflecting the advancement of the company’s priority programs, including GBS, GA and ANX1502, compared to $27.9 million for the quarter ended September 30, 2022.
General and administrative (G&A) expenses: G&A expenses were $6.9 million for the quarter ended September 30, 2023, compared to $8.2 million for the quarter ended September 30, 2022.

Gracell Biotechnologies Reports Third Quarter 2023 Unaudited Financial Results and Provides Corporate Update

Retrieved on:

Monday, November 13, 2023

ET today

Key Points:

ET today
SAN DIEGO, Calif. and SUZHOU and SHANGHAI, China, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell” or the “Company”), a global clinical-stage biopharmaceutical company dedicated to developing innovative and highly efficacious cell therapies for the treatment of cancer and autoimmune diseases, today reported third quarter unaudited financial results for the period ended September 30, 2023, and provided corporate updates.
We look forward to presenting an update with more details at ASH 2023,” commented Dr. William (Wei) Cao, founder, Chairman and CEO of Gracell.
Financial Results for Third Quarter Ended September 30, 2023
As of September 30, 2023, the Company had RMB1,707.9 million (US$234.1 million) in cash and cash equivalents and short-term investments.
Interest income for the three months ended September 30, 2023 was RMB9.9 million (US$1.4 million), compared to RMB3.6 million for the corresponding prior year period.

United States $160+ Bn Generic Drugs Markets, Competition, Forecasts and Opportunities, 2018-2022 and 2023-2028 - ResearchAndMarkets.com

Retrieved on:

Tuesday, December 12, 2023

Health, Pharmaceutical, Molecule, Safety, Conditional sentence, Prevalence, Patient, FDA, Generic drug, Ageing, Drug, Health care, Patent, Government, Pharmacy, Health insurance, Pharmaceutical industry

Generic drugs offer affordable alternatives for managing chronic diseases, making them appealing to patients, healthcare providers, and payers.

Key Points:

Generic drugs offer affordable alternatives for managing chronic diseases, making them appealing to patients, healthcare providers, and payers.
Increasing Drug Shortage Across the Region: Drug shortages of brand-name drugs can lead to increased utilization of generic alternatives.
Healthcare providers and pharmacies may turn to generic drugs during shortages, ensuring uninterrupted patient care and promoting their utilization.
Company Profiles: Detailed analysis of the major companies present in the United States Generic Drugs Market.

CN Bio PhysioMimix Organ-on-a-Chip Data Supports Inipharm’s INI-822 for Metabolic Liver Disease Treatment Now in Clinical Testing

Retrieved on:

Monday, December 4, 2023

Biotechnology, Pharmaceutical, Health, Clinical Trials, Molecule, OOC, Research, DSM-IV codes, Non-alcoholic fatty liver disease, Prevalence, MPS, Hepatology, Patient, Therapy, Drug discovery, NIAB, HSD17B13, NASH, Pharmaceutical industry

The use of in vitro OOC for early evidence of efficacy for INI-822 demonstrates the transformative potential of these models to provide human-relevant data within preclinical programmes.

Key Points:

The use of in vitro OOC for early evidence of efficacy for INI-822 demonstrates the transformative potential of these models to provide human-relevant data within preclinical programmes.
Loss-of-function variants of this gene are known to be associated with reduced incidence risk and severity of multiple liver diseases.
As part of the recent regulatory submission, CN Bio’s Contract Research Services team utilised the Company’s PhysioMimix OOC Systems and NASH ‘in-a-box' (NIAB) kit to generate critical data to determine compound efficacy.
For more information, visit: https://cn-bio.com/
Inipharm Initiates Dosing in Phase 1 Study of Its Small Molecule Inhibitor of HSD17B13: https://www.businesswire.com/news/home/20231130655005/en/
View source version on businesswire.com: https://www.businesswire.com/news/home/20231204544807/en/

Service Insight Unveils Revolutionary AIoT Solution for Biotech, Pharma, and Clinical Diagnostic Laboratories

Retrieved on:

Wednesday, November 29, 2023

Service Insight Unveils Revolutionary AIoT Solution for Biotech, Pharma, and Clinical Diagnostic Laboratories

Key Points:

Service Insight Unveils Revolutionary AIoT Solution for Biotech, Pharma, and Clinical Diagnostic Laboratories
In a data-centric era, laboratories in biotech, pharmaceuticals, and diagnostics are increasingly adopting AI to gain a competitive edge and make data-driven decisions.
To bridge this gap, Service Insight introduces the Smart Lab solution, a pivotal capability designed to capture essential missing data for driving AI models that address scientific reproducibility.
Anthony Uzzo, CEO of Service Insight, shares his vision: "At Service Insight, our mission is to be a catalyst for digital transformation in how businesses manage their operations.
Elevating Clinical Diagnostics & Hospital Labs:
Service Insight introduces AIoT solutions to enhance efficiency and traceability in Clinical Diagnostic and Hospital Labs.

Boehringer Ingelheim Expands Usage of Genedata Biologics to DMPK Operations

Retrieved on:

Monday, November 20, 2023

Molecule, Drug metabolism, QC, Boehringer Ingelheim, DMPK, Organization, Partnership, Fine chemical, Pharmacokinetics, Genedata

BASEL, Switzerland, Nov. 20, 2023 /PRNewswire-PRWeb/ -- Genedata, the leading provider of enterprise software solutions for biopharmaceutical R&D, today announced that Boehringer Ingelheim, one of the largest producers of biopharmaceuticals in the world, has expanded usage of the Genedata platform to include the Drug Metabolism and Pharmacokinetics (DMPK) group in the US. The DMPK US operations use Genedata Biologics® as part of their life-cycle management strategy of critical reagents (including analytical reference standards and drug products) used in the non-clinical and clinical bioanalytical activities of prospective new biopharmaceutical drugs.

Key Points:

The DMPK US operations use Genedata Biologics ® as part of their life-cycle management strategy of critical reagents (including analytical reference standards and drug products) used in the non-clinical and clinical bioanalytical activities of prospective new biopharmaceutical drugs.
We have been using Genedata Biologics across our early biologics discovery operations for many years and are very excited to onboard the US-DMPK group as this is a major step towards having complete end-to-end digital tracking of all BI's therapeutic candidates.
"After an initial evaluation, the DMPK group was eager to get onto the Genedata Biologics platform and take advantage of having all information pertaining to critical reagents in one place.
One of the strengths of Genedata Biologics is the platform's ability to integrate with Boehringer Ingelheim's laboratory instruments, sample management systems, and corporate IT infrastructure.